Mirum Pharmaceuticals (MEX:MIRM) Payments of Debt: MXN0 Mil (TTM As of Mar. 2026)


MEX:MIRM Mirum Pharmaceuticals Inc MEX:MIRM
46 GF Score
Price MXN1,256.12
GF Value MXN849.96
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Payments of Debt?

Mirum Pharmaceuticals MEX:MIRM 46 Payments of Debt is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:MIRM with a GF Score™ of 46/100 and a GF Value™ of MXN849.96. The stock has 6 warning signs investors should review.

Mirum Pharmaceuticals's Payments of Debt for the three months ended in Mar. 2026 was MXN0 Mil.

Mirum Pharmaceuticals's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0 Mil.

Mirum Pharmaceuticals Payments of Debt Related Terms

Mirum Pharmaceuticals Payments of Debt Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Payments of Debt Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:MIRM
46GF Score
Mirum Pharmaceuticals Inc MEX:MIRM
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of MXN0 Mil mean?
Mirum Pharmaceuticals (MEX:MIRM) has a Payments of Debt of MXN0 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' Payments of Debt too high?
Mirum Pharmaceuticals' current Payments of Debt is MXN0 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Payments of Debt compare to RYTM and SYRE?
Mirum Pharmaceuticals' Payments of Debt of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Payments of Debt is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Payments of Debt of MXN0 Mil. The stock's GF Value™ is MXN849.96, compared to a current price of MXN1,256.12 — trading 47.8% above its estimated fair value. The current Payments of Debt is MXN0 Mil. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Payments of Debt is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,256.12 is trading 47.8% above its estimated GF Value™ of MXN849.96.

Key valuation signals for MEX:MIRM:

  • Payments of Debt: MXN0 Mil
  • GF Value™: MXN849.96 vs. price of MXN1,256.12 (47.8% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score

Get the complete analysis for MEX:MIRM

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,256.12
Price
MXN849.96
GF Value